跳至主要内容
临床试验/NL-OMON46578
NL-OMON46578已完成不适用

Prospective study evaluating ctDNA as a biomarker for treatment response in head and neck squamous cell carcinoma* - PECA

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 70 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • >= 18 years of age
  • Stage II-IV carcinoma of the larynx, hypopharynx, oral cavity or HPV negative oropharynx, or stage II-III HPV positive oropharyngeal carcinoma, according to the American Joint Committee on Cancer (AJCC) staging manual 8th edition
  • Indication for curative radiotherapy with or without concurrent radiosensitizer
  • WHO performance status 0-2
  • signed written informed consent

排除标准

  • Metastastic disease
  • Radiotherapy with palliative intent
  • Diagnosis of any other malignancy within 5 years prior to start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g. surgery, radiation or castration).

研究者

发起方
Antoni van Leeuwenhoek Ziekenhuis

相似试验